Actively Recruiting
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Led by Fudan University · Updated on 2026-03-25
134
Participants Needed
1
Research Sites
183 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast cancer (TNBC) in the first-line teatment of unresectable locally advanced or metastatic TNBC.
CONDITIONS
Official Title
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 18 to 70 years
- ECOG Performance Status of 0 or 1
- Expected lifetime of at least three months
- Histologically confirmed metastatic or locally advanced triple-negative breast cancer (TNBC) with basal-like immune suppressed (BLIS) subtype
- Recurrent or metastatic breast cancer stage; local recurrence confirmed as unresectable
- No prior chemotherapy or targeted therapy for metastatic TNBC
- At least one measurable or non-measurable lesion not previously treated with radiation
- Major organ functions are essentially normal
- Women of childbearing potential agree to use contraception or remain abstinent as required
- Ability to understand the study protocol and willingness to participate and follow up
You will not qualify if you...
- Symptomatic, untreated, or active central nervous system metastases
- Significant cardiovascular disease
- Ongoing Grade 1 or higher adverse reactions from previous treatments (except hair loss or exceptions noted by researchers)
- Major surgery within 3 weeks before starting trial treatment (minor outpatient surgery allowed)
- Pregnancy, breastfeeding, or plans to become pregnant during the study
- Other cancers within the past 5 years, except cured cervical carcinoma in situ or certain skin cancers
- Inability to swallow, chronic diarrhea, intestinal blockage affecting drug use or absorption
- Uncontrolled fluid buildup like pleural fluid or ascites
- Participation in other antitumor drug trials within 4 weeks before starting this trial
- Long-term non-healing wounds or fractures
- Active hepatitis B or C infection or abnormal liver function
- Known allergies to trial drug components or other monoclonal antibodies
- History or risk of gastrointestinal bleeding within the past 6 months
- Abdominal fistula, gastrointestinal perforation, or abscess within 28 days before trial
- Significant proteinuria or urine protein >1.0 g/24h
- Hypertension not controlled to normal range despite treatment (systolic >140 mmHg or diastolic >90 mmHg)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Breast cancer institute of Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
Z
Zhimin Shao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here